Desvenlafaxine ER 50mg

Route: Oral, extended-release capsule/tablet.

• Administer once daily with or without food.
• Swallow whole — do not crush, chew, cut, or dissolve; the extended-release matrix is designed for gradual drug release over 24 hours.
• Consistent daily timing is recommended to maintain steady-state plasma concentrations.

Final dosing is determined by the prescribing clinician based on indication, patient tolerability, and response. General pharmacological reference points include:

• Starting dose: 50 mg once daily is the established effective dose for major depressive disorder.
• Off-label vasomotor symptoms: 50–100 mg/day has been studied; no additional benefit demonstrated above 50 mg for most patients.
• Renal impairment: Reduce to 25–50 mg/day in moderate-to-severe impairment; maximum 25 mg/day or 50 mg every other day in ESRD.
• Discontinuation: Taper gradually over at least two weeks to minimize discontinuation-emergent symptoms (dizziness, nausea, headache, irritability).

All dosage adjustments are at the discretion of the prescriber.

• Desvenlafaxine: Selectively inhibits the serotonin transporter (SERT) and norepinephrine transporter (NET), with approximately 10-fold greater selectivity for serotonin over norepinephrine. Increased synaptic serotonin and norepinephrine modulate hypothalamic thermoregulatory centers (relevant to vasomotor symptoms) and limbic mood circuits. Weak dopaminergic reuptake inhibition is also present. Desvenlafaxine does not bind to muscarinic, histaminergic, or alpha-adrenergic receptors at clinically relevant concentrations.

Clinical Context: Desvenlafaxine is FDA-approved for major depressive disorder (MDD) in adults. Off-label, it is used as a non-hormonal option for menopausal vasomotor symptoms (hot flashes and night sweats) in patients with contraindications or preferences against estrogen therapy. Multiple randomized controlled trials demonstrate statistically significant reductions in moderate-to-severe hot flash frequency and severity at 100 mg/day versus placebo.

Monitoring Considerations:

• Blood pressure: Monitor at baseline and periodically; SNRIs may elevate blood pressure.
• Suicidality: Black box warning for increased suicidal ideation in patients ≤24 years — monitor closely at treatment initiation and dose changes.
• Serum sodium: Monitor in elderly patients at risk for SIADH/hyponatremia.
• Lipids: Dose-dependent increases in fasting cholesterol and triglycerides have been reported.
• Renal function: Adjust dose based on creatinine clearance.

Contraindications:

• Hypersensitivity to desvenlafaxine succinate, venlafaxine, or any formulation excipient.
• Concurrent use or use within 14 days of a monoamine oxidase inhibitor (MAOI) — risk of serotonin syndrome.
• Initiation in patients receiving linezolid or intravenous methylene blue (serotonergic agents).

Warnings & Precautions:

• Serotonin syndrome: Risk increased with concomitant serotonergic agents (triptans, other SNRIs/SSRIs, fentanyl, tramadol, lithium, tryptophan).
• Hypertensive crisis: Control pre-existing hypertension before initiating; monitor blood pressure regularly.
• Angle-closure glaucoma: Pupil dilation may precipitate an episode in susceptible patients.
• Bleeding risk: SNRIs affect platelet serotonin; use caution with NSAIDs, aspirin, warfarin.
• Mania/bipolar activation: Screen for bipolar disorder before initiating; may precipitate manic episode.
• Neonatal adaptation syndrome: Third-trimester exposure may cause respiratory distress, feeding difficulties, and jitteriness in neonates.
• Discontinuation syndrome: Taper gradually; abrupt cessation may cause dizziness, nausea, headache, anxiety.

Drug Interactions:

• MAOIs (contraindicated — serotonin syndrome risk)
• Serotonergic drugs: triptans, tramadol, linezolid, methylene blue, St. John's Wort (additive serotonin risk)
• Anticoagulants/NSAIDs: increased bleeding risk
• CYP3A4 inhibitors: minor increases in desvenlafaxine exposure (not clinically significant for most)

Common Side Effects: Nausea, dizziness, insomnia, hyperhidrosis, constipation, dry mouth, decreased appetite, sexual dysfunction (decreased libido, delayed orgasm), and elevated blood pressure. Nausea and dizziness are most prevalent in the first 1–2 weeks of therapy.

Store at controlled room temperature (20–25°C / 68–77°F); excursions permitted to 15–30°C. Keep in original container, tightly closed, away from moisture and light. Keep out of reach of children. Compounded preparations carry a beyond-use date assigned by Genesis Compounding — do not use after this date. Do not use if capsule appears damaged or discolored.

Is this compound FDA-approved?

Desvenlafaxine succinate is an FDA-approved active pharmaceutical ingredient (brand name Pristiq®) for major depressive disorder. This preparation is compounded by Genesis Compounding as a patient-specific, prescriber-directed 503A preparation and is not itself FDA-approved as a finished compounded drug product.

How does this differ from the branded version?

This compounded extended-release formulation uses the same active ingredient (desvenlafaxine succinate) at the same strength. Compounding allows customization of dose, excipients, or delivery form per prescriber direction when a commercially available product does not meet the patient's specific clinical needs.

Can this medication be used for hot flashes?

Off-label use of desvenlafaxine for menopausal vasomotor symptoms has been studied in multiple randomized trials showing significant reduction in hot flash frequency and severity. Prescribers should weigh benefits and risks on a patient-specific basis. This is not an FDA-approved indication.

What should I do if a dose is missed?

Instruct the patient to take the missed dose as soon as remembered unless it is close to the time of the next dose. Do not double doses. If two or more consecutive doses are missed, the prescriber should be consulted before resuming, especially to assess discontinuation symptoms.

How should this medication be discontinued?

Abrupt discontinuation may cause dizziness, nausea, headache, irritability, and abnormal dreams. The prescriber should taper the dose gradually, typically over several weeks, adjusting based on the patient's response and duration of therapy.